Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, today announced that it has selected Fabrinet (NYSE: FN), a leading provider of advanced precision optical and electronic manufacturing services, for the production of its Vista(R)-X90 lidar, which will be deployed in the industry’s largest ADAS lidar series production program. According to the update, Cepton selected Fabrinet for its deep expertise in advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services for the production of high-performance, proprietary assemblies of its Vista-X90 lidars. “At Cepton, our goal is to be the world’s go-to supplier of automotive lidar solutions, and working with an OEM-trusted and validated manufacturing partner is a crucial part of that effort,” said Dr. Jun Pei, co-founder and CEO of Cepton. “Fabrinet has earned a strong reputation within the automotive industry with its excellent service and precision-manufacturing expertise. We are excited to work with Fabrinet to accelerate the production of our Vista-X90 lidar, as the partnership is a crucial step towards getting our lidars into an unprecedented volume of automobiles through our flagship ADAS lidar program.” To view the full press release, visit https://ibn.fm/2PJio

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

• Reliability – The durable design uses common, easily attainable materials.
• Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
• Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
• Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Wednesday's trading session at $1.61, up 4.5455%, on 201,161 volume. The average volume for the last 3 months is 200,519 and the stock's 52-week low/high is $1.01/$80.16.

Recent News

• Cepton Inc. (NASDAQ: CPTN) - InvestorNewsBreaks - Cepton Inc. (NASDAQ: CPTN) Enters Strategic Partnership for Production of Vista(R)-X90 Lidar
• Cepton, Inc. (NASDAQ: CPTN) Furthers Tier 1 Collaboration, Aims to Make Lidar a Standard Feature in Transportation
• TinyGemsBreaks - Cepton Inc. (NASDAQ: CPTN) Working to Make Lidar a Standard Feature of Today's Cars, Key Component of Future Autonomous Vehicles

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

A recent press release by Orcosa highlights a statement made by former U.S. President Bill Clinton to the effect that the results of a clinical trial by NYU Langone, which tested the effectiveness of CBD in managing pain, were very encouraging. Clinton, who has in the past revealed that he used cannabis in his youth, has been keenly following the progression of these CBD trials. Orcosa is a life sciences company that is focused on modernizing the way drugs are taken through the use of its next-generation drug-delivery technology. The company supplied the CBD products used in the trial, which contained TR Processing’s CBD ingredient. As more positive comments about different cannabinoids come from leading figures such as Clinton, public perceptions could change a lot faster among all demographic segments, and the cannabis products made by companies such as Flora Growth Corp. (NASDAQ: FLGC) will enjoy an even bigger market in the years to come.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

• Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
• Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
• Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

• Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
• Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
• Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Wednesday's trading session at $0.693, up 5.0477%, on 631,825 volume. The average volume for the last 3 months is 630,507 and the stock's 52-week low/high is $0.61/$21.45.

Recent News

• Flora Growth Corp. (NASDAQ: FLGC) - 420 with CNW - Clinton Calls CBD Trial's Results Encouraging for Pain Treatment
• 420 with CNW - VA Clarifies That Veterans Working in Cannabis Industry Can Apply for Home Loans
• CannabisNewsBreaks - Flora Growth Corp. (NASDAQ: FLGC) Poised for First-Mover Advantage

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various conditions, has announced preliminary data from a feasibility study using Kernel Flow. The results indicate that ketamine-induced changes in functional connectivity last for several days after administration of the substance. “Kernel Flow is the first easy-to-use, wearable device that collects and measures real-time brain activity before, during and after a psychedelic experience. Using the device, the study successfully measured the neuro-effect of ketamine over 11 days, confirming changes in functional connectivity that are consistent with current scientific research,” a recent article reads. “By utilizing Flow, we will now be able to quantifiably gather real-time functional brain activity during our clinical and research studies evaluating psychedelic-based therapeutics,” said Cybin CEO Doug Drysdale. “Measuring where and how psychedelics work in the brain unlocks new frontiers of discovery in this space.” To view the full article, visit https://ibn.fm/xLtdk. Research from recent years has revealed that psychedelic drugs have the potential to revolutionize mental health treatment. Psychedelics are federally classified as Schedule I drugs with no medical potential, however, making it nigh impossible for the people who would benefit from psychedelic treatments to access them. Fortunately, this may soon change after the U.S. House of Representatives passed psychedelic therapy amendments that would expand research into the benefits of psychedelics and allow veterans to access psychedelic-assisted PTSD treatments. The bipartisan amendments by Reps. Alexandria Ocasio-Cortez and Dan Crenshaw would increase access to psychedelics treatments for military veterans as well as active members of the military. They were added to the annual National Defense Authorization Act. The $839 billion defense bill was passed by 149 Republicans and 180 Democrats. It remains to be seen whether these amendments will be passed into law and how they will improve the conditions under which companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) operate as these organizations seek to develop revolutionary treatments for some of the most hard-to-treat psychiatric conditions.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Wednesday's trading session at $0.59, up 3.5996%, on 1,045,523 volume. The average volume for the last 3 months is 1.041M and the stock's 52-week low/high is $0.3903/$3.38.

Recent News

• Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) - House Approves Amendments on Psychedelic Therapy in Defense Spending Measure
• PsychedelicNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unlocking 'New Frontiers of Discovery' with Kernel Flow
• Is It Safe to Smoke DMT?

BlockQuarry Corp. (OTC: BLQC)

The QualityStocks Daily Newsletter would like to spotlight BlockQuarry Corp. (OTC: BLQC).

The crypto market has had a rough go in the past few months. Most cryptocurrencies have lost more than 50% of their value, and the crypto market as a whole lost billions of dollars in value. Bitcoin, which had dropped in price from $69,000 in November to around $20,000 in June, dropped by 3.5% last week to trade at $20,831 by the end of the week. Ethereum, which was also down by almost 50% by June and traded for as low as $900, was up by 11.1% to trade at $1,357. Polygon went up by a whopping 19.46% to trade at $0.70, Uniswap was up by 11.6% to $7.07 and Monero went up by $10.5% to $139.39. These news items notwithstanding, plenty of companies, including BlockQuarry Corp. (OTC: BLQC), are hard at work coming up with different ways through which blockchain can serve ordinary individuals. The future remains bright for this new technology, especially for cryptocurrencies, despite the recent hiccups,.

BlockQuarry Corp. (OTC: BLQC), through its in-house initiatives and strategic partnerships, has invested in growing operations targeting the telehealth and cryptocurrency mining industries.

The company specializes in strategic brand development and early growth facilitation. Management maneuvers its proprietary companies through critical stages of market development, including conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency.

Mission

The company’s core mission is to enhance these sectors by implementing innovative services and products that are ready to meet the demands of a changing world. To that end, ISW Holdings leverages its strategic expertise, resources and innovative software to establish market-leading companies and partnerships, thereby ensuring success in their chosen industries.

Cryptocurrency Mining

The start of 2021 saw a massive resurgence in interest surrounding bitcoin and cryptocurrency mining. In mid-February, bitcoin prices hit an all-time high of greater than $57,000, and heightened demand for cryptocurrency mining power has played a key role in exacerbating a global shortage of semiconductors and computer components.

With a foothold in the cryptocurrency mining space, ISW Holdings has placed significant focus on expanding its position and capitalizing on this momentum. Recent highlights include:

• February 9, 2021: The company announced that its revolutionary Pod5 Cryptocurrency Mining Pod will be powered up into full operational launch at the Bit5ive renewable energy cryptocurrency mining facility in Pennsylvania on February 12, 2021.
• February 11, 2021: The company announced that it is in negotiations to purchase a large number of miners (between 300 and 900) in preparation for its coming Phase 3 expansion in mining volume.
• February 23, 2021: The company announced its entry into a comprehensive Hosting and Maintenance Agreement prior to going online with its new ASIC s17 miners.
• March 2, 2021: The company announced that it has successfully tripled its active cryptocurrency mining fleet with the addition of two new POD5IVE datacenters.

“As we continue to bring our miners online, we want our shareholders to be able to track the expansion and profitability of the company’s mining activity given the sharp rising trend in bitcoin prices,” Alonzo Pierce, President and Chairman of ISW Holdings, stated in a news release. “It currently costs about $11K in computing power to mine a single bitcoin. Bitcoin is pricing at over five times that level, making this is an exceptional ROI opportunity, and our responsibility to our shareholders is clear: continue to invest, expand and execute.”

Business Innovations

ISW Holdings’ diverse portfolio reflects the growing demand for essential services in a dynamic modern operational landscape. Some of the company’s current holdings and partnerships include:

• Bit5ive LLC: ISW Holdings operates a joint venture with Bit5ive, a global leader in cryptocurrency mining. The joint-venture agreement enables ISW Holdings to collaborate with the experienced team at Bit5ive to innovate the infrastructure needed to run profitable and efficient crypto mining projects.
• Proceso LLC: ISW Holdings has partnered with Proceso LLC to create high-density processing and mobile data centers powered by renewable energy. These innovations will allow Proceso to offer lower-cost and diverse services to its clients, including hosting and colocation services to growing sectors such as the gaming industry and cryptocurrency mining.
• PHH Health: The company’s home health division answers the growing need for home care services in a world where health care delivery is changing and an increasingly large aging community is looking for efficient and effective ways of accessing health care.
• Volum: The company’s logistics and supply chain management division is designed with the core goal of increasing supply chain efficiency, which is recognized as one of the key aspects of successfully growing any business.

Market Opportunity

ISW Holdings’ recent activity in the cryptocurrency mining sector has positioned it to capitalize on the forecast expansion of the cryptocurrency market in the coming years. According to data from MarketsandMarkets, the cryptocurrency space was valued at $1.03 billion in 2019 and is projected to reach $1.40 billion in 2024, achieving a CAGR of 6.18% during the forecast period.

The report suggests that major drivers for this growth will be the transparency of the underlying blockchain technology, the high volume of remittances in developing countries, the high cost of international remittance, expected fluctuations in monetary regulations and sustained investment in the cryptocurrency space by venture capital firms.

Management Team

Terry Williams is the Chief Executive Officer and Director of ISW Holdings. Mr. Williams brings to the company more than 30 years of experience in accounting and information systems, logistics, insurance and transportation. With a Bachelor’s and Master’s degree in accounting and management information systems, he amassed considerable corporate experience at UPS (NYSE: UPS), where he took several logistical roles, managing more than 2,000 employees and a budget of more than $10 billion. Mr. Williams also serves as president of Airware Transportation and Logistics and Chief Financial Officer of AVI Insurance Caribbean. In 2013, he received the National Airport Minority Advisory Council Award for mastering skills in the aviation industry.

Alonzo Pierce is the company’s President and Chairman. He brings a wealth of business development and wealth management experience to the ISW team, having spent the past 20 years building recognizable brands in multiple industry sectors. Mr. Pierce has launched enterprises in life-styled brands which were delivered to high-profile, high-net worth families and individuals. He has worked in the adult beverage industry, establishing a formidable background in marketing and brand creation. Pierce has a B.A. from Baylor University and has received multiple awards in the adult beverage industry, including ‘Outstanding Sales Performance in the Southern Region’ for Sapphire Brands. Pierce also served as a national liaison to a Super-Regional Bank’s private wealth division. In addition to his for-profit endeavors, Pierce has served on multiple charitable boards, sourcing funding for JRA, food insecure families and housing insecure families.

Kristina Mahoney-Brown is Secretary, Treasurer and Director of ISW Holdings. With more than 20 years of experience providing tax and financial consulting to real estate companies, as well as investors, developers and construction companies, Ms. Mahoney-Brown has gained solid business expertise and market knowledge and prides herself on staying abreast of the latest industry trends. Her professionalism, impeccable work ethic and advanced marketing strategies have earned her the nickname ‘The Tax Diva’. Mahoney-Brown has a Bachelor’s in accounting, a Master’s in taxation and a Master’s in business administration, specializing in personal financial planning.

BlockQuarry Corp. (BLQC), closed Wednesday's trading session at $0.4905, up 6.3991%, on 1,013,416 volume. The average volume for the last 3 months is 1.013M and the stock's 52-week low/high is $0.18/$3.78.

Recent News

• BlockQuarry Corp. (OTC: BLQC) - Highlights of Last Week's Crypto News
• Wire Network Unveils Crypto Interoperability Wallet
• Capitalizing on the Generational Washout in Crypto Markets (RIOT, BLQC, COIN, MARA, HIVE, HUT, SQ, MSTR)

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)

The QualityStocks Daily Newsletter would like to spotlight Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF).

Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) has leveraged its management’s experience, collectively having financed and invested in early-stage venture companies for over 25 years, in the sourcing, financing and building successful companies. “We have laid a strong foundation within the Eat Well Group investment platform, and we are very enthusiastic about the trajectory of our portfolio. Our portfolio companies are well positioned to capture global pulse demand and accelerate the scale of their better-for-you consumer products for years to come,” said Marc Aneed, Eat Well’s director, president and CEO. A recent article discusses significant expected growth for the food tech sector, stating, “It is projected that the plant-based foods market will comprise up to 7.7% of the global protein market by 2030, valued at $162 billion, up from $29.4 billion in 2020. Many analysts have even likened the food tech market to the early days of the internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize how society functions and people experience nutrition.” To view the full article, visit https://ibn.fm/odCjV

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF), headquartered in Vancouver, British Columbia, is a publicly traded vertically integrated plant-based foods company combining the best of agribusiness, foodtech, and CPG brands to supply the world with innovative, delicious, and better-for-you foods. The company supplies Beyond Meat, Ingredion, Nestle, General Mills and more. It is on track to generate $60 million in revenue for 2021 and is projecting $100 million in revenue for 2022.

Eat Well’s management team has an extensive record of sourcing, financing and building successful companies across a broad range of industries and maintains a current investment mandate on the health and wellness industry. The team has financed and invested in early-stage venture companies for more than 25 years, resulting in the ability to construct a portfolio of opportunistic investments intended to generate superior risk-adjusted returns. Eat Well’s strategic advisory board includes pioneers in the plant-based foods industry, including HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, and Jeff Dunn, CEO of Bolthouse Farms who previously held senior leadership positions at both Campbell Soup Company and The Coca Cola Company.

The company’s plant-based investment thesis is centered on growing its seed-to-market operations, which include raw ingredients, processing, pulse fractionation, unique IP and premium consumer packaged goods (CPG). Eat Well Group is building a unique ecosystem that can supply these essential cornerstone needs for society. The company has plant-based foods and nutrition experts specializing in the latest science and original thinking for what consumers want most – high quality and affordability in healthy, clean and simple products.

Eat Well focuses on intellectual property, product portfolio development and long-term value creation for stakeholders in a rapidly expanding industry. As an emergent sector globally, plant-based foods represent a double-digit annual growth category, with more than 35% of the world’s supply of pulse proteins coming from Canada.

Portfolio

On July 31, 2021, Eat Well Group acquired Belle Pulses Ltd., one of the top pulse processors in Canada. Belle Pulses has been operating for over 40 years and had over $60 million in sales in 2020. The company counts a broad range of customers in over 35 countries, including global strategic food companies and major ingredient distributors. Currently, Belle produces nearly 100,000 tons of fully traceable seed and product, yielding over 26,000 tons of pure plant protein.

Eat Well also owns 100% of Sapientia Technology Inc. Led by Dr. Eugenio Bortone – one of the world’s preeminent food scientists and extrusion processing experts and the inventor of Frito-Lay’s Twisted Cheetos – Sapientia has filed four patents around the “protein curl” and crispy-puff-style snack. By focusing on texture and crunch, Sapientia’s patents solve one of the major problems that large scale snack food companies have struggled with for years – how to offer appealing texture and flavor in a guilt-free, not fried, natural and healthy alternative to the majority of snack food products available today.

Eat Well owns a 51% share of Amara Organic Foods, with an option to acquire additional ownership up to 80 percent. Amara, one of the fastest-growing baby food brands in America, is a food technology company that uses science and proprietary IP that locks in taste and texture to make healthy, organic, non-GMO, plant-based, convenient baby and children’s food possible for modern-day families. From baby food to toddler food and beyond, Amara is driven by the belief that setting kids on the right path from a young age will help them live better, feel better and think better for the rest of their lives. Amara’s revenues have grown by more than 400% since January 2021, and the brand’s success has drawn media coverage from business news outlets including Forbes and TechCrunch.

Market Outlook

According to an August 2021 report from Bloomberg Intelligence, the plant-based foods market is expected to experience explosive growth, comprising up to 7.7% of the global protein market by 2030 at a value of over $162 billion, up from $29.4 billion in 2020. Bloomberg notes that plant-based alternatives are here to stay, and that consumption will grow rapidly. Plant-based food sales in 2020 grew twice as fast as overall food sales, according to Polaris Market Research.

Pulse proteins (fava, yellow pea, etc.) are a foundational ingredient to most plant-based foods due to their high protein content and their readily available, affordable supply.

Many analysts view the food tech market as similar to the early days of the Internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize the way society functions and people experience nutrition.

The sector continues to experience significant M&A transactions. Recently, Sol Cuisine was acquired by PlantPlus Foods LLC, a major South American protein producer, in an all-cash transaction valued at approximately $126 million, or 6x revenue.

Management Team

Marc Aneed is President and Director of Eat Well Group. His 20-year career in CPG started at The Quaker Oats Company/PepsiCo, where he worked on iconic brands like Gatorade. He previously was at Glanbia PLC, a global nutrition company, where he led Amazing Grass, a leading plant nutrition and supplement company with over $100 million in retail sales. He also led Glanbia’s Sports Nutrition brands in North America with over $750 million in retail sales. Mr. Aneed has launched dozens of successful consumer products, driving over $1 billion in collective retail sales.

Mark Coles is the company’s Chief Investment Officer. He is a veteran CPG senior executive specializing in the plant-based foods sector. For the past decade, Mr. Coles has spearheaded global plant-based start-up initiatives, culminating in a 2020 acquisition by an international New York Stock Exchange-listed food ingredient company. He has over 25 years of experience in CPG-focused strategy, mergers and acquisitions and project financing.

Patrick Dunn is Eat Well Group’s Vice President, Finance. He is the founding partner of Dunn, Pariser & Peyrot and has a track record of building highly successful agribusinesses throughout North America and other international markets. As a testimony to his business portfolio work, Mr. Dunn and his firm have won multiple industry awards for accounting, finance and business management.

Barry Didato is the company’s Vice President, Strategy. He is focused on the development of strategic revenue channels, sales partnerships, and international distribution for Eat Well Group. Mr. Didato brings extensive strategic sales capabilities and an extensive network of contacts in the industry to the company. Prior to joining Eat Well Group, he served for over 18 years as a senior advisor for several ultra-high net worth family offices and numerous innovative wellness, nutrition, medical, and food businesses.

Strategic Advisory Board

HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, is a firm supporter of clean energy and the humane treatment of animals. He is also a vocal supporter of the private sector in the Middle East. A member of the Saudi Arabian Royal Family, Prince Khaled was born in Stanford and spent his youth in Riyadh under the mentorship of his father, philanthropist HRH Prince Alwaleed bin Talal Al Saud, Chairman of Kingdom Holding Company. He is also the Founding Chairman of KBW Investments and serves across several boards. He invests in an array of successful but diverse global businesses – from promising technology startups to established companies. Today, with holdings on three continents, Prince Khaled stands at the gateway between the Middle East’s evolving economies and the Western world. Consistently, Prince Khaled’s focus is on ventures and ideas at the intersection of innovation and economic growth.

Jeff Dunn has over 30 years of experience in agriculture and packaged food, including senior leadership positions with Bolthouse Farms, Campbell Soup Company and The Coca Cola Company, among others. He is an Operating Partner at Butterfly and focuses primarily on the agriculture & aquaculture and food & beverage product sectors. Prior to joining Butterfly, Mr. Dunn was the President of the Campbell Fresh division of Campbell Soup Company from 2015 to 2016, where he was in charge of building Campbell’s scale and accelerating its growth in the rapidly expanding packaged fresh segments and categories across the retail perimeter.

Eat Well Investment Group Inc. (OTC: EWGFF), closed Wednesday's trading session at $0.16255, up 3.4685%, on 3,188 volume. The average volume for the last 3 months is 3,188 and the stock's 52-week low/high is $0.13158/$1.00.

Recent News

• Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) - ESGBreaks - Eat Well Investment Group Inc.'s (CSE: EWG) (OTC: EWGFF) Portfolio 'Well Positioned to Capture Global Pulse Demand'
• Eat Well Investment Group Inc.'s (CSE: EWG) (OTC: EWGFF) Sapientia to Collaborate With Other Portfolio Companies Following Completion of Payment Agreement
• Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) Reports Growth, Ongoing Optimism for Natural Food Brands Amid Market Pressures

AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF)

The QualityStocks Daily Newsletter would like to spotlight AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF).

At least 20 million Americans live with autoimmune disorders, but there’s still much we don’t know about these conditions. The disorders usually occur when, for some reason, the immune system goes haywire and begins to attack healthy tissue. In addition to not knowing exactly what causes autoimmune disorders, we still haven’t figured out a way to cure them. Recently, however, researchers studying immune disorders discovered a novel method of triggering the immune system via certain proteins. This discovery could provide scientists with the chance to know more about autoimmune conditions such as lupus and scleroderma. A lot can go wrong when the immune system goes haywire and attacks the body, which is why there is some urgency in the work being done by entities such as AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) to come up with interventions that retrain immune systems so that the malfunctions triggering different autoimmune illnesses can be arrested.

AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) is a fully integrated, publicly traded, early-stage life science enterprise dedicated to delivering therapeutic interventions to public health through discovery, innovation and successful collaborations in the life science industry. The company’s leadership drives discovery programs for clinical complexities presented by malnutrition, viral infectious diseases and the inflammatory response system.

AREV’s business model leverages the core competency of producing proprietary compounds through its innovative extraction methodologies, scientific advisory board (SAB), experienced staff, and executive leadership to drive its product pipeline. AREV’s strategy is to generate revenue from selling its branded products via its online technology platform, Medicine Merchant™, an enterprise marketing platform built to enable consumers to have access to novel therapeutic approaches to human nutrition, endemic diseases, and neglected chronic related co-morbidities. The company also expects to generate revenue from toll processing and government procurement of its products that address malnutrition and related health issues.

AREV is focused on innovations in biomedicine and maintains a significant footprint in clinical human nutrition utilizing proprietary protein blends and terpenes, complimented with vitamins and minerals. The company has utilized its expertise to design and deliver innovation in therapeutic interventions using its exclusive botanical, fungi and marine compounds to address medical conditions driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV uses its proprietary extractions allowing characterizations from botanical and marine sources in therapeutic foods and medicines that comprise its development pipeline.

Development of AREV’s pipeline is fostered by collaborations with academic centers, clinical research organizations and government institutions committed to facilitating discovery of promising new clinical approaches presented in peer reviewed journals. AREV operates under the guidance of its SAB and a growing number of strategic collaborations with CROs and academic research centers, including the Linus Pauling Institute at Oregon State University.

AREV is a member of both BIOTECanada and The Biotechnology Industry Organization (BIO):

• BIOTECanada is the national industry association with over 200 members located nationwide, reflecting the diverse nature of Canada’s health, industrial and agricultural biotechnology sectors.
• BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the United States and 30+ countries.

Products

AREV’s end-product and target categories include therapeutic interventions, botanical drugs, ready-to-use therapeutic food (RUTF), enteral nutrition formulas and early-stage small molecule antiviral therapeutics demonstrating novel mechanisms of action.

Wright and Well Branded Line

Wright and Well Branded Line is the company’s branded line of therapeutic cannabinoid and terpene-based formulations. The topical line includes solutions for burns, wounds, skin disorders and muscle relief, as well as a lubricant for intimacy. The oral line addresses inflammation, heart health, high blood pressure and viral infections. These products are currently produced at CBD99, a licensed processor in Sandy, Oregon. The company also has a strategic relationship with a Canadian licensed hemp and cannabis processor in Vancouver, British Columbia.

SUS-TAINN™

The company’s products in the RUTF category are branded under SUS-TAINN™ (Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs). SUS-TAINN™ is the flagship line of products stemming from AREV’s collaboration with Voynich Biosciences.

RUTFs like SUS-TAINN™ are the cornerstone to international famine response and currently represent more than 20 percent of public health commodity procurement spending. SUS-TAINN™ is purchased by agencies ranging from the U.S. Department of State AID for International Development to the World Food Program and is distributed by an increasingly substantial number of non-governmental organizations.

RESTORE™

The company’s enteral nutrition product is branded as RESTORE™. For patients experiencing caloric compromise, enteral nutrition, a liquid form of nourishment, is often required. RESTORE™, the initial enteral formulation from AREV, is based on organic plant nutrition for patient populations who have demonstrated overt clinical need for rational enhanced caloric intake and micronutrient supplementation.

RESTORE™ provides a proprietary blend of high-quality proteins, antioxidants, minerals and proven anabolic agents, combined with pre- and probiotics. The company plans to submit for Medicaid formulary inclusion and reimbursement designations in various jurisdictions characterized by the Ryan White CARE Act during the second half of 2022.

REV-I1™

REV-I1™ is the company’s small molecule drug discovery model for phytomedicinalization, based on advanced computational characterization and next generation affinity selection that affords new opportunities in HIV antiretroviral research. REV inhibition offers a critical approach to inhibiting HIV replication and addressing viremia in highly conserved sanctuary regions.

Phytomedicinal therapeutic discovery and development offer clinically viable approaches to a wide range of scientific challenges that currently elude successful contemporary interventions. A cornucopia of diverse validated compounds allows AREV to explore a distinguished range of promising approaches that are in stages of pre-clinical validation. Combining AREV’s versatile extraction capability with highly sensitive analytical techniques (LC-MS, MS-MS) is expected to allow new medicinal chemistry to be identified and characterized, leading to therapeutic candidates in the company’s commercial drug discovery platform.

Market Overview

A report from Verified Market Research valued the global plant protein market at $29.4 billion in 2020 and forecast that it could surpass $162 billion by 2030, which would make up 7.7% of the global protein market, according to a report released in August by Bloomberg Intelligence.

The RUTF market was valued at $363.72 million in 2019 and is projected to reach $807.89 million by 2027, growing at a CAGR of 10.5% for the forecast period. The market is primarily driven by the efforts of governments and non-governmental organizations to reduce the rate of severe acute malnutrition. Moreover, changing trends and growing developments related to diet-related deficiencies, as well as increasing incidences of famine and disasters, are likely to fuel the growth of the RUTF market in the near future, according to the report.

Management Team

Michael Withrow is the founder, chairman and CEO of AREV. He is a successful natural products and technology entrepreneur with more than 25 years of experience. He has started and sold companies and has worked with companies such as CAVA Health Care (formerly Alternative Extracts Inc.), North American BioExtracts Inc., and Canadian Pacific Phytoplankton Ltd. He has also served as president and CEO of a specialty cannabis technology company.

Kevin Phelps, CPA, is a director at AREV. He is CEO and president of Immune Therapeutics Inc., a bio-pharmaceutical company. He began his career with Price Waterhouse before joining Eastman Kodak Company as part of an executive team that successfully spun out the Bio Products Division into Genencor International Inc., an international industrial bio-chemicals company. He later joined Trillium Group, a regional private equity firm, as a partner, where he served on behalf of the firm as CFO of Vaccinex Inc., a vaccine development company, and chairman of AccuMed Inc., a medical device company. He has served as Chairman of Oyagen, a biotech that over the past decade has developed drug discovery methods that have enabled it to explore vulnerabilities in HIV, Ebola and coronaviruses.

Denby Greenslade is corporate secretary and interim CFO at AREV. She has served as corporate secretary and director for several companies in the mining, biotech and IT industries and has more than 15 years of corporate secretarial, corporate governance, and securities regulation experience. She graduated from Simon Fraser University with a Bachelor of Arts in Communication.

Allan Echino is a director at AREV. He was a founder and director of Corlac Resources, an oil producer, and Calroc Industries, an oil service company based in Alberta. Mr. Echino arranged funding for a licensed producer in the cannabis sector and quickly learned the business and health benefits of cannabis and mushrooms.

Mel Maxwell is a director at AREV. During his 40-plus year career, he has founded six companies. His degrees in business and computer science initially took his career toward IT ventures that entailed software development, IT consulting, e-commerce solutions, real estate development, pathogen remediation solutions and wholesale vehicle aggregation. He finds continued enjoyment in consulting with other businesses and entrepreneurs.

Scientific Advisory Board

Roscoe M. Moore, Jr., DVM, MPH, PhD, a former United States Assistant Surgeon General, provides strategic planning for AREV’s nutritional and drug discovery platforms as chairman of the company’s scientific advisory board. Dr. Moore is a member of the board of advisers of the Institute of Human Virology (IHV) and the board of directors of the Global Virus Network associated with IHV, University of Maryland Medical Center. IHV is the first research institute in the U.S. to link basic science, population studies, and clinical trials in an effort to develop new vaccines and treatments; its 80 faculty members contribute to research on pandemic pathogens, ranging from COVID-19 to HIV.

Dr. Moore served with the United States Department of Health and Human Services (HHS) and was responsible, for the last 12 years of his career, for global development support within the Office of the Secretary, HHS, with primary emphasis on implementing innovations in essential health care commodity procurement programs for resource-challenged countries. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service, entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Rear Admiral. Dr. Moore worked at the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming senior epidemiologist within the National Institute for Occupational Safety and Health of the U.S. Centers for Disease Control and Prevention (CDC), where he also served as an epidemic intelligence service officer.

Robert Melamede, PhD, received his doctorate in molecular genetics and biochemistry from the University of the City of New York Graduate Center, focusing on base excision repair of free radical damages in DNA. For decades, he led laboratory efforts in a world-class, federally funded lab, where he discovered endonuclease VIII. Dr. Melamede did a sabbatical at the Scripps Institute and subsequently established an in vitro monoclonal antibody facility at the University of Vermont, developing antibodies to free radical damages in DNA and to DNA repair enzymes. Working with a collaborator, Dr. Melamede worked on metabolism and cancer cells as a professor and chair of the biology department at the University of Colorado at Colorado Springs. He co-founded Cannabis Science Inc., a public company, retiring as the company’s chief executive in 2014. Dr. Melamede continues his innovative research in the private sector.

Harold Smith, PhD, is the founder, CEO, and president of Oyagen Inc., a biotechnology company developing therapeutics for various disease states, including HIV and cancer. Dr. Smith is also a tenured professor of biochemistry and biophysics at the University of Rochester, School of Dentistry and Medicine, with additional appointments as a professor in genetics and pathology and as a member of the Center for RNA Biology.

Richard Van Breemen, PhD, is a Professor of Medicinal Chemistry in the Department of Pharmaceutical Sciences of the College of Pharmacy at Oregon State University. His research interests include cancer prevention by dietary antioxidants and prostate cancer prevention by the carotenoid lycopene, mass spectrometry-based pharmacological screening of natural products and combinatorial libraries for drug discovery, and high throughput screening to assess drug metabolism, toxicity and bioavailability. Dr. Van Breemen made The Analytical Scientist’s Power List in 2020 and 2021. His work in biomedical mass spectrometry earned him an initial spot, and he clocked in the Top 100 analytical scientists from around the world on the Power List in 2021.

Dr. Blake Hawley is the founder & CEO of Motega Health Inc. Dr. Hawley has worked in animal health, pharma and food across 23 countries and four continents. He holds an MBA from KU and his doctorate in veterinary medicine and zoology degrees from NC State. He serves on multiple non-profit advisory boards, including the KU MBA Advisory Board. Dr. Hawley is a 2017 graduate of Pipeline Entrepreneurs and a graduate of the Village Capital Agricultural 2016 Entrepreneur Cohort.

Dr. Hawley previously served as the General Manager of Australasia; Regional General Manager of Russia and Central Eastern Europe (consisting of 22 countries); and Managing Director of the United Kingdom and Ireland for Hill’s Pet Nutrition, a division of Colgate-Palmolive. His experience includes 10 years of profit and loss responsibilities in these territories, with consistent double-digit annual revenue growth in each of the 10 years. He oversaw products competing in the arthritis, dermatology, obesity, gastrointestinal, urinary, and cancer markets, among others. Dr. Hawley also has background in e-commerce, data analytics, and social media and most recently served as Worldwide Director of Global Digital for Hill’s Pet Nutrition.

Uma Dhanabalan, MD, MPH, FAAFP, MRO, CMS, advises AREV on product development and formulation. She is the founder and CEO of Global Health & Hygiene Solutions LLC, whose mission is to promote wellness and prevent illness locally and globally and runs an independent practice at Uplifting Health & Wellness in Cambridge, Massachusetts. Dr. Dhanabalan, a fellow of the American Academy of Family Physicians, graduated from UMDNJ, Newark, New Jersey, with her medical degree and trained in family medicine at MUSC in Charleston, South Carolina; she earned her master’s degree in public health from Harvard’s School of Public Health in Boston, Massachusetts, and continued her training at Harvard in occupational and environmental medicine.

Special IP Advisor

Douglas Sorroco practices in all areas of intellectual property law including patent, trademark, copyright, technology, and e-commerce and assists clients with intellectual property matters requiring litigation, licensing, technology counselling and complex transactions.

Mr. Sorroco is ranked in Band 1 (the top band) for intellectual property law by the highly regarded Chambers USA: America’s Leading Lawyers for Business 2021, and he was selected for inclusion in The Best Lawyers in America® 2022 for Litigation – Intellectual Property, Litigation – Patent, Patent Law and Technology Law. In 2021, Best Lawyers named him the Oklahoma Lawyer of the Year for Technology Law. In 2021, Managing Intellectual Property continued to rank Doug as an IP Star. Mr. Sorroco was selected for inclusion in Oklahoma Super Lawyers 2021 and was also selected by attorney peers for inclusion in Oklahoma Super Lawyers – Rising Stars Edition (2010).

AREV Life Sciences Global Corp. (OTC: AREVF), closed Wednesday's trading session at $0.089, up 58.9286%, on 1,000 volume. The average volume for the last 3 months is 1,000 and the stock's 52-week low/high is $0.054/$0.32616.

Recent News

• AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) - Study Reveals Proteins That Can Trigger Immune System Malfunction
• New Study Finds Some Viruses Can Make You Tastier to Mosquitoes
• New Research Says Immune Cell Proliferation May Be Associated with Multiple Sclerosis Onset

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

We have seen several major players enter the marijuana drink market in the recent past as more products are launched, despite the segment being in its infancy. While the focus in the past had been THC-infused drinks, we have seen interest in the wellness benefits linked to CBD growing as well. Cannabis drinks are popular with consumers for various reasons, including fewer health concerns, discreetness, ease of consumption and less stigma when compared to other marijuana consumption methods such as smoking. These drinks also have faster onset of effects as the cannabinoids are quickly absorbed into an individual’s bloodstream under the tongue and through the mouth and the stomach. Marijuana beverages also come in different doses of CBD and THC, with most having both cannabinoids in them. As the different product segments grow and reach maturity, companies such as Advanced Container Technologies Inc. (OTC: ACTX), which makes products targeting indoor growers, are likely to also see accelerating demand for their products.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Wednesday's trading session at $0.7, even for the day, on 18 volume. The average volume for the last 3 months is 18 and the stock's 52-week low/high is $0.54/$2.10.

Recent News

• Advanced Container Technologies Inc. (OTC: ACTX) - 420 with CNW - The Marijuana Drinks Segment Looks Poised for Long-Term Growth
• CannabisNewsBreaks - Advanced Container Technologies Inc. (ACTX) Offers Solution to Grow High-Quality Crops Anywhere Year-Round
• 420 with CNW - Health Canada Remains Quiet on Timeline for Reviewing Marijuana Law

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that Dr. Markus Roggen, president and chief science officer for Delic Labs, was named to the Cannabis Scientist Power List for the third consecutive year. Due to his commitment to creating a body of work on cannabis research that will have a positive, lasting effect on the industry, Dr. Roggen is consistently recognized as one of the most influential figures in the processing professionals category. Under Dr. Roggen’s leadership, Delic Labs will transfer its cannabis sector expertise and experience to position in psychedelic research and safety testing. The lab has secured Health Canada 56 exemptions for chemistry analytics on psilocybin mushrooms and has received psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc., a wholly-owned subsidiary of Psilobrain Therapeutics Inc. In addition, the lab intends to perform research and tests on a host of compounds outside of psychedelic mushrooms, including MDMA and LSD. Within the next months, Delic Labs expects to receive a dealer’s license with the intent of commercializing psilocybin research and associated intellectual property (“IP”) for medical and research purposes. To view the full press release, visit https://ibn.fm/XgDTP

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

• Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
• Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
• Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
• Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

• 32 million people in the U.S. have used psychedelics at least once
• 17% of all American adults between 21 and 64 have used psychedelics at least once
• $500 billion is spent in the U.S. every year on prescription drugs
• $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
• The anxiety disorder and depression treatment market is estimated at $16 billion
• $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Wednesday's trading session at $0.0436, even for the day, on 68,330 volume. The average volume for the last 3 months is 68,330 and the stock's 52-week low/high is $0.03/$0.315.

Recent News

• Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) - InvestorNewsBreaks - Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Celebrates Third Recognition of Delic Labs' Dr. Markus Roggen to Cannabis Scientist Power List
• The DEA Could Be Sued Again Over Stance on Psilocybin, Cancer Patients
• States That Have Made Advancements Toward Legalizing Psychedelics

DPCM Capital Inc. (NYSE: XPOA)

The QualityStocks Daily Newsletter would like to spotlight DPCM Capital Inc. (NYSE: XPOA).

DPCM Capital (NYSE: XPOA) recently entered into a definitive transaction agreement with D-Wave Systems Inc., whereby, upon closing of the transaction, shares of the pending parent company – D-Wave Quantum Inc. – are expected to trade on the NYSE under ticker symbol QBTS. D-Wave Systems, a leader in quantum computing systems, software and services, and the only company building both quantum annealing and gate-based quantum computers, and Mastercard (NYSE: MA) recently announced a multi-year strategic alliance to champion the acceleration and adoption of quantum computing solutions. According to the announcement, D-Wave and Mastercard will collaborate on the research and development of quantum-hybrid applications in areas such as consumer loyalty and rewards, cross-border settlement and fraud management. “We are heralding in the next wave of computing. Just like the creation of the PC, the emergence of the internet and the proliferation of smartphones and voice assistants, it is our belief that quantum will have far-reaching and industry-disrupting impact, especially in the financial services sector,” said Alan Baratz, CEO of D-Wave. “D-Wave and Mastercard have a shared vision of harnessing the power of technology to positively affect business and society. This alliance supports that vision by delivering quantum innovation that will tackle increasingly complex problem sets across applications like optimized loyalty programs, fraud management and anti-money laundering in financial services and, ultimately, unlock more value for customers.” To view the full press release, visit https://ibn.fm/YVC07

DPCM Capital Inc. (NYSE: XPOA), a special purpose acquisition company, on February 9, 2022, announced its entry into a definitive transaction agreement with D-Wave Systems Inc., a company with approximately 20 years of experience in pioneering superconducting annealing quantum computers. Upon closing of the transaction, shares of D-Wave Quantum Inc. – a newly formed company that will be the parent company of D-Wave Systems and DPCM Capital – are expected to trade on the NYSE under ticker symbol ‘QBTS’.

The transaction, which is subject to the satisfaction of customary closing conditions, is expected to enhance D-Wave’s leadership in commercial quantum computing and accelerate quantum use cases into significant customer segments.

D-Wave is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

DPCM Capital Inc. (NYSE: XPOA), closed Wednesday's trading session at $9.97, off by 0.050125%, on 132,985 volume. The average volume for the last 3 months is 132,934 and the stock's 52-week low/high is $9.65/$10.33.

Recent News

• DPCM Capital Inc. (NYSE: XPOA) - InvestorNewsBreaks - DPCM Capital Inc.'s (NYSE: XPOA) Pending Partner D-Wave Forms Alliance to Champion Quantum Computing Solutions
• DPCM Capital Inc. (NYSE: XPOA) Is 'One to Watch'
• D-Wave Systems Inc. and DPCM Capital, Inc. Announce Effectiveness of Registration Statement

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that its global clinical trial for a potentially pivotal brain cancer treatment will expand patient eligibility following an amendment to its protocol for the study. “CNS has been enrolling patients in its phase II clinical trial for novel drug candidate Berubicin, which has shown promise in fighting the aggressive brain cancer glioblastoma (‘GBM’),” explains a recent article. “The trial will compare Berubicin’s performance to the standard of care chemotherapy agent Lomustine, aiming to establish that Berubicin is at least as effective as Lomustine and potentially better because of Berubicin’s reported capacity to cross the blood-brain barrier to attack tumors directly. Crossing the blood-brain barrier gives Berubicin novel status because other anthracycline chemotherapy agents have thus far been unable to accomplish that feat, resulting in an average life expectancy of just over a year for GBM patients once they are diagnosed with the nearly always fatal illness. The ultimate goal of the clinical trial is to establish potential improvements in overall survivability for the patients using Berubicin.” To view the full article, visit https://ibn.fm/WGIv7

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $0.23, off by 1.709%, on 228,601 volume. The average volume for the last 3 months is 221,362 and the stock's 52-week low/high is $0.22/$1.85.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - BioMedNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Expanding Patient Eligibility in Potentially Pivotal Berubicin Trial
• Preclinical Study Uncovers Potential Key to Treating Deadly Brain Tumors
• CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expands Patient Eligibility for Brain Cancer Drug Trial, Receives Approval from U.S. FDA for Protocol Amendment

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

• As awareness of the long-term hazards of concussive head injuries for young athletes has increased during the past decade, advocates and business enterprises have stepped up to improve coach responsiveness to players’ condition
• While efforts primarily focus on assessing injury, Odyssey Health Inc. is developing a product it hopes to become the first drug device with FDA approval for treating a concussed patient after injury
• Odyssey is enrolling patients in a Phase 1 human clinical trial after completing pre-clinical studies in laboratory animals
• The medical research company’s assets include treatments for patients who may have undiagnosed heart disease, patients choking on some type of obstruction lodged in their throats and patients dealing with a rare neurodegenerative disorder

Sports-related concussions have gained a growing degree of attention during the past decade, thanks largely to the activism of a junior high school football player severely injured during a game who continued to play despite a hard impact to the head he had experienced (https://ibn.fm/bb79K). Medical device innovator and biopharmaceutical product developer Odyssey Health (OTC: ODYY) is focusing on the concussion injury issue from the vantage point of treating individuals after they’ve been hurt. There is no medication approved by the U.S. Food and Drug Administration (“FDA”) at this point for treating specific concussion injuries, but Odyssey is preparing for human trials of a product it believes may fill that gap. Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. Two-time Olympic gold medalist Abby Wambach joins the latest podcast to speak on behalf of Odyssey Health, a medical technology company developing a drug/device combination intended to treat concussion. Wambach is a member of Odyssey’s sports advisory board, which aims to support the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. “I had a unique, long career playing for the Women’s National Team. I played in many Olympics and World Cups, won a bunch of golds and, in my retirement (I’ve been retired for six years), I’ve had a lot of time to reflect on the time that I played,” Wambach said. “I played soccer for 30 years, and one of the biggest concerns that I have going into the rest of my life is my brain health and wellness. Of course, a lot of us only think of concussions and CTE as it relates to NFL football, but the reality is that brain trauma happens in every sport.” To view the full press release, visit https://ibn.fm/dao0s

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio

Pharmaceuticals

Odyssey has two pharmaceutical products in development:

• PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
  • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
• PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
  • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

• CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
  • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
• Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
  • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Wednesday's trading session at $0.1987, off by 0.65%, on 40,496 volume. The average volume for the last 3 months is 40,496 and the stock's 52-week low/high is $0.11/$0.64.

Recent News

• Odyssey Group International Inc. (OTC: ODYY) - InvestorNewsBreaks - Odyssey Health Inc. (ODYY) Featured in Stock2Me Podcast
• Odyssey Health, Inc. (ODYY) Responds to Growing Concerns About Concussion Head Injuries with Drug Device in Clinical Trial
• InvestorNewsBreaks - Odyssey Health Inc.'s (ODYY) Spokesperson Brett Favre to Be Featured on RedChip Money Report(R)

Lottery.com Inc. (NASDAQ: LTRY)

The QualityStocks Daily Newsletter would like to spotlight Lottery.com Inc. (LTRY).

Lottery.com Inc. (NASDAQ: LTRY) is a next generation platform where consumers can play the lottery online – in browser or via smartphone app. The platform offers users access to official lottery games sanctioned by their individual states and also provides lottery data to more than 400 digital publishers, including Google and Amazon Alexa.

Lottery.com was founded in 2015, launching at the LAUNCH festival and soon turning into a leader in the industry. With headquarters in Austin, Texas, the company is dedicated to helping advance the lottery industry into the digital age and works closely with state regulatory bodies to achieve this goal.

The company recently entered into a definitive agreement for a business combination with special purpose acquisition company Trident Acquisitions Corp. (NASDAQ: TDAC) (“Trident”), which will result in Lottery.com becoming a publicly listed company. Once the transaction is complete, the combined company will be trademarked as Lottery.com, with its common stock to remain listed on Nasdaq under ticker symbol ‘LTRY’.

Lottery.com Online Platform

The Lottery.com online platform works closely with state regulators, advancing the lottery into the digital age. With the online platform, the company offers enhanced regulatory capabilities by leveraging innovative blockchain technology and capturing the untapped market of digitally native players.

Players go online in a browser or through a mobile application to use the interface. The process includes:

• Players Choose a Game: Players can play officially state sanctioned multi-state games and other games offered in the states in which they live. Players can also find winning numbers, jackpot totals, draw dates and more for hundreds of other lottery games around the world.
• Players Pick Numbers: Players can play their lucky numbers or do a quick pick of randomized numbers in as simple as two taps. “Tap, Tap, Ticket!”
• A Safe and Secure Way to Play: Purchases for up to 50 tickets can be made at one time through the online interface. Lottery.com handles everything after purchase, letting users know when they win.
• Collect All Winnings: Consumers keep 100% of their winnings. All winnings stay in the Lottery.com balance for future ticket purchases, or a cashout can be requested. Company representatives contact winners who hit big jackpots, instructing them on the redemption process.

A Better Way to Play the Lottery

Lottery.com has an innovative e-commerce platform that is using blockchain to maintain an accurate ledger. From 2016 to 2020, Lottery.com grew gross revenue at a CAGR of 363%, and it forecasts gross revenue equal to approximately $71 million in 2021, $279 million in 2022, and $571 million in 2023.

Lottery.com is leveraging a successful playbook, with $398 billion in global lottery sales but only 6.7% online penetration. The large market opportunity is expected to shift to online transactions within the next decade.

The platform is currently available in 12 states across the United States, and the company plans to expand to 34 by the end of 2023. Global expansion is also on the horizon, with partnership plans in Turkey and Ukraine.

Key features that make the Lottery.com experience unique include:

• All the Games Users Love – For consumers who live in applicable LIVE states, Powerball and Mega Millions are available right from the mobile application.
• Convenience – Lottery.com makes playing the lottery on mobile devices easy. After setting up an account, users can begin playing in moments or set reminders to play when the jackpot is high.
• Easy Cashouts – Users can cash out winnings straight to a bank account, safely and securely, with no commissions.

The company is also gamifying charitable giving, fundamentally changing how nonprofits engage with donors and raise funds. WinTogether.org is a platform designed to offer charitable donation sweepstakes to incentivize donors to take action by offering large cash prizes and once-in-a-lifetime experiences.

Strong Advisory Board Presence

Lottery.com is expected to continue to gain support, leaning on the experience of its advisory board and notable investors from the venture capital, gaming and entertainment industries. These include:

• Jason Robins, CEO of DraftKings Inc. (NASDAQ: DKNG)
• Ben Narasin, Venture Partner of NEA
• Peter Diamandis, Chairman of XPRIZE Foundation
• Matthew Le Merle, Co-Founder and Managing Partner of Fifth Era and Keiretsu Capital
• Paraag Marathe, President of Enterprises and EVP of Football Operations for the San Francisco 49ers
• Jamie Gold, The Poker Philanthropist

Management Team

Tony DiMatteo is the Co-Founder and Chief Executive Officer of Lottery.com. He is a serial entrepreneur and highly sought-after industry speaker and thought leader. He has been featured in The Wall Street Journal, Forbes, VentureBeat, TechCrunch Inc. and more for his approach to entrepreneurship, the gaming industry and cryptocurrency.

Matt Clemenson is the Co-Founder and Chief Commercial Officer of Lottery.com. He is responsible for the company’s strategy. Mr. Clemenson was steeped in corporate and enterprise engineering processes at Hotwire and Expedia before going on to be CEO at LesConcierges, the world’s largest concierge company, which merged into John Paul and sold to Accor Hotels. Clemenson and DiMatteo have been partners for more than 10 years.

Ryan Dickinson is the company’s President and Chief Operating Officer. He has a diverse background in business, technology, product, design and sales, which has aided him in producing many successful outcomes throughout his career. Notably, as Senior Vice President of a SaaS company, Mr. Dickinson produced profitability from a negative $1.4 million division within the first year by reinventing the product offerings, streamlining processes and establishing a go-to-market strategy. Additionally, he produced three record breaking revenue years in a row for AccuWeather, the world’s largest weather provider, by increasing every KPI for all flagship properties by no less than 5%.

Luc Vanhal is the company’s Chief Financial Officer. He has served in C-level executive roles since the 1990s, including a nine-year tenure for The Walt Disney Company (NYSE: DIS) from 1990 to 1999. From 2001 to 2004, he managed the development of the World of Warcraft massively multiplayer game, which, by the end of 2020, still had over five million active subscribers. As the CFO of Lottery.com, Mr. Vanhal leads the company’s global finance organization, with treasury responsibility, accounting, analysis and financial planning.

Lottery.com Inc. (LTRY), closed Wednesday's trading session at $0.82, off by 1.7964%, on 235,592 volume. The average volume for the last 3 months is 235,481 and the stock's 52-week low/high is $0.753501/$17.50.

Recent News

• Lottery.com Inc. (NASDAQ: LTRY) - InvestorNewsBreaks - Lottery.com (NASDAQ: LTRY) Releases Q1 Financial, Operational Results
• InvestorNewsBreaks - Lottery.com (NASDAQ: LTRY) Announced Conference Call to Discuss Q1 2022 Results
• InvestorNewsBreaks - Lottery.com (NASDAQ: LTRY) Releases Q4, Full-Year Results